AGIO - NASDAQ
Agios Pharmaceuticals, Inc.
$27.68
-1.1%Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotAgios Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Agios Pharmaceuticals, Inc. Cash Flow Statement
AGIO • NASDAQ
| Agios Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||
-412.8M | 673.7M | -352.1M | -231.8M | -356.5M | -329.3M | -411.5M | -346M | -314.7M | -198.5M | -117.7M | -53.5M | -39.4M | -20.1M | -23.7M | |
5.2M | 5.7M | 6.6M | 8.6M | 9.2M | 18.8M | 8.1M | 7.2M | 6.4M | 5.7M | 3.3M | 1.4M | 1.4M | 1.2M | 801K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.1M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.8M | 6.7M | -10.7M | |
52.6M | 42.8M | 44.8M | 49.3M | 53.5M | 0.0 | 72.4M | 73.4M | 47.8M | 42.1M | 32M | 11.5M | 3M | 742K | 371K | |
15.1M | -1.1B | 23.7M | -119.1M | -76.7M | 17.8M | 8.5M | -3.8M | 29K | 773K | 572K | 538K | 284K | 297K | 391K | |
(628K) | (43.2M) | (1.6M) | (0.0) | (16.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-33M | -19.8M | -19.1M | -16.4M | -36.8M | 2M | -46M | -35.1M | -24.8M | 188.5M | 4.9M | -19.3M | -25.6M | -38.4M | 17.6M | |
-373M | -389.8M | -296.1M | -309.5M | -407.3M | -290.8M | -370.6M | -304.4M | -285.2M | 38.6M | -76.9M | -59.4M | -56.4M | -49.5M | -15.2M | |
INVESTING ACTIVITIES | |||||||||||||||
-4.3M | -1.7M | -999K | -4.9M | -5.7M | -14.1M | -12.2M | -7M | -4.6M | -9.9M | -20.2M | -2.2M | -1.3M | -1.5M | -1.9M | |
(0.0) | (40K) | (0.0) | (132.7M) | (0.0) | (0.0) | -103.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-641.8M | -1.5B | -417.9M | -1B | -1.4B | -557M | -488.6M | -933.3M | -688.7M | -506.1M | -353.2M | -837.2M | -146M | -88.5M | -105.9M | |
1B | 818.4M | 674.7M | 1.1B | 829.8M | 647.7M | 592.2M | 666.5M | 635.4M | 396.6M | 501.7M | 505.5M | 60.1M | 113M | 85.5M | |
-10M | 1.1B | -16.2M | 0.0 | 1.8B | -803K | 103.5M | -266.8M | -53.3M | -109.4M | 148.5M | 571K | -85.9M | 24.5M | 0.0 | |
(377.2M) | (363.4M) | (239.6M) | (243.3M) | (1.2B) | (75.7M) | (91.4M) | -273.8M | -57.9M | -119.4M | (128.3M) | -333.3M | -87.2M | (23M) | -22.4M | |
FINANCING ACTIVITIES | |||||||||||||||
8.7M | 14.4M | 5.4M | 2.7M | -802.5M | 11.3M | 277.2M | 516.2M | 270.3M | 162.2M | 0.0 | 333.6M | 126.1M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | -331K | -578K | -336K | -113K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | -802.5M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 0.0 | 0.0 | 37.3M | 250.5M | 12.5M | 29.8M | 14.9M | 7.6M | 6.4M | 1.6M | -2.2M | 142K | 57K | |
8.7M | 14.4M | 5.4M | 2.4M | -765.8M | 261.5M | 289.6M | 546M | 285.1M | 169.8M | 6.4M | 335.2M | 123.9M | 142K | 77.4M | |
CASH FLOW SUMMARY | |||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
12.9M | -12M | -51.1M | -63.9M | 75.7M | 46.5M | 10.4M | -32.2M | -58M | 89M | 57.7M | -57.5M | -19.7M | -26.4M | 39.8M | |
76.2M | 88.2M | 139.3M | 203.1M | 127.4M | 80.9M | 70.5M | 102.7M | 160.8M | 71.8M | 14M | 71.6M | 91.3M | 117.7M | 77.9M | |
89.1M | 76.2M | 88.2M | 139.3M | 203.1M | 127.4M | 80.9M | 70.5M | 102.7M | 160.8M | 71.8M | 14M | 71.6M | 91.3M | 117.7M | |
-377.3M | -391.5M | -297.1M | -314.4M | -413.1M | -304.9M | -382.8M | -311.4M | -289.9M | 28.6M | -97.1M | -61.6M | -57.7M | -51M | -17.1M |
SEC Filings
AGIO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 18, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | October 30, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 04, 2025 | August 04, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | July 31, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your AGIO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.